Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Ntla-2001 entities : Teva pharmaceutical industries ltd save search
Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
Published: 2022-09-16 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: 0.74%
H: 0.91%
C: -0.74%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: 0.62%
H: 1.12%
C: 0.01%
NTLA | $21.53 -1.37% -1.37% 650K
|
Health Technology
|
| O: -3.76%
H: 0.36%
C: -0.44%
ntla-2001 treatment ongoing crispr therapy study
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR)
Published: 2022-06-24 (Crawled : 12:00) - biospace.com/
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: 8.01%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: 3.49%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: 0.77%
H: 0.18%
C: 0.07%
NTLA | $21.53 -1.37% -1.37% 650K
|
Health Technology
|
| O: 3.45%
H: 5.18%
C: 1.71%
ntla-2001 treatment phase 1
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose
Published: 2022-06-24 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: 8.01%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: 3.49%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: 0.77%
H: 0.18%
C: 0.07%
NTLA | $21.53 -1.37% -1.37% 650K
|
Health Technology
|
| O: 3.45%
H: 5.18%
C: 1.71%
ntla-2001 treatment phase 1
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: -1.15%
H: 1.44%
C: 1.12%
NTLA | $21.53 -1.37% -1.37% 650K
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
ntla-2001 crispr disease intel phase 1 therapy
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: -1.15%
H: 1.44%
C: 1.12%
NTLA | $21.53 -1.37% -1.37% 650K
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
ntla-2001 crispr disease intel phase 1 therapy
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 26M
|
AGBA | $2.97 137.6% 57.48% 66M
|
Finance
EDBL | News | $6.59 75.27% 41.8% 2M
|
ZAPP | $4.44 50.2% 33.12% 370K
|
n/a
MTC | $2.24 43.59% 30.67% 6M
|
Technology Services
OPRT | News | $3.15 40.0% 29.13% 12M
|
Finance
SHIM | $3.045 35.33% 26.23% 870K
|
HKIT | $1.33 30.39% 24.16% 390K
|
Technology Services
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
OST | $0.5 25.0% 21.88% 280K
|
Your saved searches
Save your searches and get alerts when important news are released.